Sonus expands relationship with Abbott
Ultrasound contrast developer Sonus Pharmaceuticals of Bothell,WA, has extended its relationship with Abbott Laboratories toinclude the clinical development and marketing of Sonus' EchoGenagent in the U.S.Last week's deal builds on a relationship between
Ultrasound contrast developer Sonus Pharmaceuticals of Bothell,WA, has extended its relationship with Abbott Laboratories toinclude the clinical development and marketing of Sonus' EchoGenagent in the U.S.
Last week's deal builds on a relationship between Sonus and Abbottthat began in 1993 for manufacturing of EchoGen. Under the newagreement, Abbott will pay Sonus $31 million in up-front, clinicalsupport, and milestone payments in return for U.S. marketing rights.In addition, Abbott paid $4 million for warrants to acquire 500,000shares of Sonus stock, equal to about 6% of shares outstanding.Sonus will receive 47% of net EchoGen revenues in the U.S. andthe company retains some co-promotion rights to EchoGen in theU.S.
EchoGen has completed phase III radiology and cardiology trialsin the U.S. and Sonus expects to file a new drug application forthe agent this year, followed by a filing with the European MedicinesEvaluation Agency. French contrast firm Guerbet has rights toEchoGen in Europe, while Daiichi Pharmaceutical retains marketingrights for the product in the Pacific Rim.
Emerging AI Algorithm Shows Promise for Abbreviated Breast MRI in Multicenter Study
April 25th 2025An artificial intelligence algorithm for dynamic contrast-enhanced breast MRI offered a 93.9 percent AUC for breast cancer detection, and a 92.3 percent sensitivity in BI-RADS 3 cases, according to new research presented at the Society for Breast Imaging (SBI) conference.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
Can Abbreviated Breast MRI Have an Impact in Assessing Post-Neoadjuvant Chemotherapy Response?
April 24th 2025New research presented at the Society for Breast Imaging (SBI) conference suggests that abbreviated MRI is comparable to full MRI in assessing pathologic complete response to neoadjuvant chemotherapy for breast cancer.
Clarius Mobile Health Unveils Anterior Knee Feature for Handheld Ultrasound
April 23rd 2025The T-Mode Anterior Knee feature reportedly offers a combination of automated segmentation and real-time conversion of grayscale ultrasound images into color-coded visuals that bolster understanding for novice ultrasound users.
